Can 'Zombie Cell' cleaners help frail cancer survivors walk faster?

NCT ID NCT04733534

Ongoing Symptom relief Sponsor: St. Jude Children's Research Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two short-term drug regimens—dasatinib plus quercetin, or fisetin alone—in 110 adult survivors of childhood cancer who are frail. The goal is to see if these 'senolytic' drugs can clear aging cells, improve walking speed, and reduce frailty. It is a first-of-its-kind pilot study, so results will guide future larger trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dasatinib plus Quercetin, or Fisetin alone
What this could lead to: If successful, this could point toward a treatment that reduces frailty and improves physical function in adult survivors of childhood cancer.
What could go wrong: This is a small, early-phase pilot study without a placebo group, so results may not be definitive. The drugs may cause side effects or fail to improve frailty.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHILDHOOD CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

childhood malignant neoplasm Frailty neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHILDHOOD CANCER FRAILTY

Contacts and locations

Show contact details

Locations

St. Jude Children's Research Hospital

Memphis, Tennessee, 38105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.